novel means for its treatment. With the goal of developing PDE10A inhibitors, early optimization of a fragment hit through rational design led to a series of potent pyrimidine PDE10A inhibitors that required further improvements in physicochemical properties, off-target activities, and pharmacokinetics. Herein we describe the discovery of an isomeric pyrimidine series that addresses the liabilities seen
PDE10A 是纹状体信号传导的重要调节因子,当受到抑制时,可以使功能失调的活动正常化。鉴于精神分裂症涉及纹状体活动功能障碍,PDE10A 抑制代表了一种潜在的新治疗方法。以开发 PDE10A
抑制剂为目标,通过合理设计对片段进行早期优化,产生了一系列有效的
嘧啶 PDE10A
抑制剂,需要在理化性质、脱靶活性和药代动力学方面进一步改进。在此,我们描述了异构
嘧啶系列的发现,该系列解决了早期化合物的缺陷,并导致了化合物18 (MK-8189) 的发明,该化合物目前处于治疗精神分裂症的 2b 期临床开发阶段。